Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Public Health Genomics ; 16(1-2): 9-16, 2013.
Article in English | MEDLINE | ID: mdl-23548712

ABSTRACT

Following the influenza epidemics, it has become clear that severity of illness is not uniform. Comorbidities and immunocompromise account for only a fraction of severe cases and do not explain the differential severity among the otherwise healthy during pandemics. During the 2009 H1N1 pandemic, a focus has been placed on better understanding of the determinants and pathogenesis of severe influenza infections. Much of the current literature has focused on viral genetics and its impact on host immunity as well as novel risk factors for severe infection (particularly within the H1N1 pandemic). The improved understanding of the cellular mechanisms and pathways involved in the pathogenesis of severe disease along with technological advances have allowed a more systematic approach to the exploration of the host genetic determinants of susceptibility and severe respiratory illness. By better defining the role of genetic variability in the immune responses to influenza, and identifying key polymorphisms that either protect against severe manifestation or those that impair the host immune response, it is possible to envision better methods to identify at-risk populations and new targets for therapeutic interventions and vaccines. This review will summarize the accumulated literature examining the immunogenetic factors associated with propensity for the development of severe pandemic H1N1 (pH1N1) manifestations. We will focus on novel and key insights gained through study of ethnic populations that appeared more vulnerable to severe disease during the 2009 H1N1 pandemic.


Subject(s)
Influenza A Virus, H1N1 Subtype , Influenza, Human/genetics , Influenza, Human/immunology , Polymorphism, Genetic , Respiratory Tract Diseases/genetics , Respiratory Tract Diseases/immunology , Alleles , Animals , Ethnicity , Genetic Predisposition to Disease , Humans , Immunoglobulin G/genetics , Immunoglobulin G/immunology , Killer Cells, Natural/immunology , Pandemics , Receptors, CCR5/genetics , Receptors, CCR5/immunology , Receptors, KIR/genetics , Receptors, KIR/immunology , Risk Factors , Severity of Illness Index , Vitamin D/immunology
2.
Mucosal Immunol ; 5(3): 277-87, 2012 May.
Article in English | MEDLINE | ID: mdl-22318497

ABSTRACT

The predominance of HIV-1 sexual transmission requires a greater understanding of the interaction between HIV-1 and the mucosal immune system. The study of HIV-1-exposed seronegative (HESN) individuals serves as a model to identify the correlates of protection and to aid in microbicide development. A total of 22 cytokines/chemokines were analyzed at the systemic and mucosal compartments in 57 HESN, 51 HIV-1-negative, and 67 HIV-1-infected commercial sex workers from Nairobi, Kenya. HESN individuals had significantly lower expression of monokine induced by interferon-γ (MIG), interferon-γ-induced protein 10 (IP-10), and interleukin-1α (IL-1α) in their genital mucosa compared with controls. HESN cytokine expression also distinctly correlates with mucosal antiproteases, suggesting that HESN individuals have a unique pattern of mucosal chemokine/cytokine expression, which may result in reduced trafficking at the mucosa. These data support the immune quiescence model of protection, whereby lower T-cell activation/recruitment at the mucosal compartment reduces HIV-1 target cell numbers and is an important component of natural protection from HIV-1.


Subject(s)
Genitalia/immunology , HIV Infections/immunology , HIV Seronegativity , HIV-1/immunology , Sex Workers , Adult , Cells, Cultured , Chemokine CXCL10/genetics , Chemokine CXCL10/metabolism , Chemokine CXCL9/genetics , Chemokine CXCL9/metabolism , Down-Regulation , Female , Genitalia/virology , HIV Infections/epidemiology , Humans , Immunity, Mucosal , Interleukin-1alpha/genetics , Interleukin-1alpha/metabolism , Kenya , Middle Aged
3.
Clin Microbiol Infect ; 16(8): 1179-86, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20670292

ABSTRACT

Influenza vaccine provides protection against infection with matched strains, and this protection correlates with serum antibody titres. In addition to antibodies, influenza-specific CD8+ T-lymphocyte responses are important in decreasing disease severity and facilitating viral clearance. Because this response is directed at internal, relatively conserved antigens, it affords some cross-protection within a given subtype of influenza virus. With the possibility of a broader A(H1N1) Mexico outbreak in the fall of 2009, it appeared worthwhile studying the degree of cellular immune response-mediated cross-reactivity among influenza virus isolates. The composition of the 2006-2007 influenza vaccine included the A/New Caledonia/20/1999 strain (comprising a virus that has been circulating, and was included in vaccine preparations, for 6-7 years) and two strains not previously included (Wisconsin and Malaysia). This combination afforded us the opportunity to determine the degree of cross-reactive cellular immunity after exposure to new viral strains. We analysed the antibody responses and the phenotype and function of the T cell response to vaccine components. The results obtained show that antibody responses to A/New-Caledonia were already high and vaccination did not increase antibody or cytotoxic T lymphocyte responses. These data suggest that repeated exposure to the same influenza stain results in limited boosting of humoral and cellular immune responses.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Influenza A virus/immunology , Influenza Vaccines/immunology , Influenza, Human/immunology , T-Lymphocytes, Cytotoxic/immunology , Adult , Antibodies, Viral/blood , Cross Protection , Cross Reactions , Hemagglutination Inhibition Tests , Humans , Manitoba , Middle Aged
4.
Immunol Cell Biol ; 78(6): 586-95, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11114968

ABSTRACT

The goal of the present study was to determine whether there were HIV-1 specific cellular immune responses among a subgroup of women within a cohort of Nairobi prostitutes (n = 1800) who, despite their intense sexual exposure to HIV-1, are epidemiologically resistant to HIV-1 infection. Of the 80 women defined to be resistant, 24 were recruited for immunological evaluation. The HIV-1-specific T-helper responses were determined by IL-2 production following stimulation with HIV-1 envelope peptides and soluble gp120. Cytotoxic T lymphocyte responses were determined by lysis of autologous EBV-transformed B cell lines infected with control vaccinia virus or recombinant vaccinia viruses containing the HIV-1 structural genes env, gag and pol. Resistant women had significantly increased HIV-1 specific T-helper responses, as determined by in vitro IL-2 production to HIV-1 envelope peptides and soluble glycoprotein 120, compared with low-risk seronegative and HIV-1-infected controls (P < or = 0.01, Student's t-test). Seven of the 17 (41%) resistant women showed IL-2 stimulation indices > or = 2.0. HIV-1-specific CTL responses were detected among 15/22 (68.2%) resistant women compared with 0/12 low-risk controls (Chi-squared test, P < 0.001). In the two resistant individuals tested, the CTL activity was mediated by CD8+ effectors. Many HIV-1-resistant women show evidence of HIV-1-specific T-helper and cytotoxic responses. These data support the suggestion that HIV-1-specific T-cell responses contribute to protection against HIV-1 infection.


Subject(s)
HIV Seronegativity/immunology , HIV-1/immunology , Immunity, Cellular , Sex Work , Adult , CD4 Antigens/immunology , Cytotoxicity Tests, Immunologic , Female , HIV Antigens/immunology , Humans , Interleukin-2/biosynthesis , Leukocytes, Mononuclear/immunology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology
5.
J Immunol Methods ; 244(1-2): 139-44, 2000 Oct 20.
Article in English | MEDLINE | ID: mdl-11033026

ABSTRACT

We sought to compare the effect of cryopreservation and storage at -30 degrees C, -70 degrees C and -150 degrees C of human whole blood versus matched peripheral blood mononuclear cell (PBMC) samples using apoptosis as an indicator of cell fitness. Following 10 weeks of storage the samples were thawed and assessed for viability (trypan blue exclusion), levels of apoptosis (using the nuclear stain bis-benzimide) and cell function (ability to be transformed by Epstein-Barr virus, EBV). When comparing storage temperatures, the levels of apoptosis in whole blood and PBMC samples stored at -30 degrees C were significantly higher than the values for samples stored at -70 degrees C or -150 degrees C (P<0.004). Whole blood samples stored at -150 degrees C had significantly less apoptosis than those stored at -70 degrees C (P<0.03). A comparison of the cell preparations showed that at all three storage temperatures there was significant sample deterioration (viability, apoptosis, and function) in whole blood relative to PBMC samples. This study indicates that careful consideration should be given to storage conditions and that apoptosis can be used as a sensitive measure of cell fitness following cryopreservation.


Subject(s)
Apoptosis/physiology , Blood Preservation/methods , Cryopreservation/methods , Leukocytes, Mononuclear , Cell Survival/physiology , Herpesvirus 4, Human , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/virology , Lymphocyte Activation
6.
J Infect Dis ; 181(5): 1581-9, 2000 May.
Article in English | MEDLINE | ID: mdl-10823757

ABSTRACT

Certain human leukocyte antigens, by presenting conserved immunogenic epitopes for T cell recognition, may, in part, account for the observed differences in human immunodeficiency virus type 1 (HIV-1) susceptibility. To determine whether HLA polymorphism influences HIV-1 susceptibility, a longitudinal cohort of highly HIV-1-exposed female sex workers based in Nairobi, Kenya, was prospectively analyzed. Decreased HIV-1 infection risk was strongly associated with possession of a cluster of closely related HLA alleles (A2/6802 supertype; incidence rate ratio [IRR], 0.45; 95% confidence interval [CI], 0.27-0.72; P=.0003). The alleles in this supertype are known in some cases to present the same peptide epitopes for T cell recognition. In addition, resistance to HIV-1 infection was independently associated with HLA DRB1*01 (IRR, 0.22; 95% CI, 0.06-0.60; P=.0003), which suggests that anti-HIV-1 class II restricted CD4 effector mechanisms may play an important role in protecting against viral challenge. These data provide further evidence that resistance to HIV-1 infection in this cohort of sex workers is immunologically mediated.


Subject(s)
Acquired Immunodeficiency Syndrome/genetics , HIV Infections/genetics , Major Histocompatibility Complex , Polymorphism, Genetic , Sex Work , Acquired Immunodeficiency Syndrome/epidemiology , Acquired Immunodeficiency Syndrome/immunology , Adult , Cohort Studies , Confidence Intervals , Disease Susceptibility/immunology , Female , HIV Infections/epidemiology , HIV Infections/immunology , HIV Seronegativity/immunology , HIV Seropositivity/genetics , HIV Seropositivity/immunology , HIV-1 , HLA Antigens/genetics , HLA-DR Antigens/genetics , HLA-DRB1 Chains , Humans , Immunity, Innate/immunology , Kenya/epidemiology , Longitudinal Studies , Time Factors
7.
AIDS ; 13(15): 2003-12, 1999 Oct 22.
Article in English | MEDLINE | ID: mdl-10546852

ABSTRACT

OBJECTIVE: A phase I trial was conducted to evaluate the safety and immunogenicity of an HIV synthetic peptide vaccine in HIV-seropositive individuals. The immunogens used in this study were PCLUS 3-18MN and PCLUS 6.1-18MN envelope peptides. METHODS: Eight HIV-infected patients received six subcutaneous injections of 160 microg PCLUS 3-18MN in Montanide ISA 51 and were followed longitudinally for a year after the first immunization. Peripheral blood mononuclear cells (PBMC) were tested for peptide-specific T helper and cytotoxic T cell (CTL) responses, HIV-1MN neutralizing antibodies and antibodies against HIV PCLUS 3 and P18 MN peptides. RESULTS: PCLUS 3-1 8MN-specific T helper responses were significantly increased at 36 weeks (P < 0.05, after adjustment for multiple comparisons) following initial immunization with PCLUS 3-18MN. A P18MN-specific CTL response, not present prior to vaccination, was observed after immunization in one patient. Serum HIV-1 MN-neutralizing antibody titers increased in each of the three patients who had low titers prior to immunization. Plasma HIV RNA levels and CD4 cell counts did not change appreciably during the study period. CONCLUSIONS: This trial demonstrates that both peptides can be safely administered to HIV-infected individuals and that PCLUS 3-18MN induces increases in HIV peptide-specific immune responses.


Subject(s)
AIDS Vaccines/administration & dosage , AIDS Vaccines/immunology , HIV Infections/prevention & control , HIV-1/immunology , Peptides/immunology , Adult , HIV Antibodies/blood , HIV Infections/immunology , HIV Seropositivity , HIV-1/chemistry , Histocompatibility Testing , Humans , Immunization , Neutralization Tests , Peptides/chemical synthesis , T-Lymphocytes/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Envelope Proteins/chemistry , Viral Load
8.
Immunol Lett ; 66(1-3): 27-34, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10203031

ABSTRACT

Variability in susceptibility to infection and disease caused by infectious agents is a characteristic of all populations. Among susceptible individuals exposed to an infection, not all become infected and among infected individuals, not all develop disease. It seems logical that variability in susceptibility to infection and disease would apply to infection and disease with human immunodeficiency viruses. However, until recently, it has been generally held that there is no natural immunity to HIV-1 and that once infected, all individuals would ultimately succumb to AIDS.


Subject(s)
HIV Infections/immunology , HIV-1/immunology , Cohort Studies , Female , HIV Infections/epidemiology , Humans , Immunity, Cellular/immunology , Immunity, Innate/immunology , Kenya/epidemiology , Male , Sex Work , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Helper-Inducer/immunology
9.
AIDS Res Hum Retroviruses ; 14(17): 1521-30, 1998 Nov 20.
Article in English | MEDLINE | ID: mdl-9840285

ABSTRACT

A small group of women (n = 80) within the Nairobi-based Pumwani Sex Workers Cohort demonstrates epidemiologic resistance to HIV-1 infection. Chemokine receptor polymorphisms and beta-chemokine overproduction have been among the mechanisms suggested to be responsible for resistance to HIV-1 infection. This study attempts to determine if any of those mechanisms are protecting the HIV-1-resistant women. Genetic analysis of CCR5 and CCR3 from the resistant women demonstrated no polymorphisms associated with resistance. Expression levels of CCR5 among the resistant women were shown to be equivalent to that found in low-risk seronegative (negative) controls, while CXCR4 expression was greater among some of the resistant women. In vitro infection experiments showed that phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs) from resistant women were as susceptible to infection to T cell- and macrophage-tropic North American and Kenyan HIV-1 isolates as were the PBMCs from negative controls. No significant difference in circulating plasma levels of MIP-1alpha and MIP-1beta were found between the resistant women and negative or HIV-1-infected controls. In vitro cultures of media and PHA-stimulated PBMCs indicated that the resistant women produced significantly less MIP-1alpha and MIP-1beta than did negative controls and no significant difference in RANTES levels were observed. In contrast to studies in Caucasian cohorts, these data indicate that CCR5 polymorphisms, altered CCR5 and CXCR4 expression levels, cellular resistance to in vitro HIV-1 infection, and increased levels of beta-chemokine production do not account for the resistance to HIV-1 infection observed among the women of the Pumwani Sex Workers Cohort.


Subject(s)
Chemokine CCL5/immunology , HIV Infections/immunology , HIV-1/immunology , Macrophage Inflammatory Proteins/immunology , Cell Membrane/metabolism , Chemokine CCL3 , Chemokine CCL4 , Female , HIV Infections/epidemiology , Humans , Immunity, Innate , Kenya/epidemiology , Receptors, CCR3 , Receptors, CCR5/biosynthesis , Receptors, CCR5/genetics , Receptors, CXCR4/biosynthesis , Receptors, Chemokine/biosynthesis , Receptors, Chemokine/genetics , Sex Work , U937 Cells
10.
J Clin Invest ; 102(9): 1758-65, 1998 Nov 01.
Article in English | MEDLINE | ID: mdl-9802890

ABSTRACT

Many people who remain persistently seronegative despite frequent HIV exposure have HIV-specific immune responses. The study of these may provide information about mechanisms of natural protective immunity to HIV-1. We describe the specificity of cytotoxic T lymphocyte responses to HIV in seronegative prostitutes in Nairobi who are apparently resistant to HIV infection. These women have had frequent exposure to a range of African HIV-1 variants, primarily clades A, C, and D, for up to 12 yr without becoming infected. Nearly half of them have CTL directed towards epitopes previously defined for B clade virus, which are largely conserved in the A and D clade sequences. Stronger responses are frequently elicited using the A or D clade version of an epitope to stimulate CTL, suggesting that they were originally primed by exposure to these virus strains. CTL responses have been defined to novel epitopes presented by HLA class I molecules associated with resistance to infection in the cohort, HLA-A*6802 and HLA-B18. Estimates using a modified interferon-gamma Elispot assay indicate a circulating frequency of CTL to individual epitopes of between 1:3,200 and 1:50,000. Thus, HIV-specific immune responses-particularly cross-clade CTL activity- may be responsible for protection against persistent HIV infection in these African women.


Subject(s)
Epitopes, T-Lymphocyte/immunology , HIV Infections/immunology , HIV-1/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Cohort Studies , Conserved Sequence , Epitopes, T-Lymphocyte/chemistry , Female , Gene Products, gag/immunology , HIV Protease/immunology , HIV Reverse Transcriptase/immunology , HLA-A Antigens/immunology , HLA-B Antigens/immunology , HLA-B18 Antigen , Humans , Immunity, Innate , Kenya , Peptides , Sequence Analysis , Sex Work , T-Lymphocytes, Cytotoxic/virology
11.
AIDS ; 12(18): 2397-406, 1998 Dec 24.
Article in English | MEDLINE | ID: mdl-9875577

ABSTRACT

OBJECTIVE: To assess whether treatment of HIV-positive children by antiretroviral drugs for a 6-month period would improve immune function significantly. DESIGN AND METHODS: Immunological assessment of 89 HIV-positive children who received protease inhibitor monotherapy for 12-16 weeks as part of phase I/II studies, followed by triple antiretroviral therapy for an additional 12 weeks, was conducted. Immunological parameters were assessed in vitro at four time points (at enrollment, at weeks 2-4, at weeks 12-16, and at weeks 24-28). Assessments included: cytokine production by monocytes, T-cell proliferation to mitogen or recall antigens (including an HIV antigen) and apoptotic cell death. Plasma levels of tumor necrosis factor (TNF)-alpha and soluble TNF receptor (sTNF-R) were also measured, in addition to CD4+ T-lymphocyte counts and viral load. In addition, limited analyses were performed on samples from 17 children after 120 weeks of therapy, including 104 weeks of triple therapy. RESULTS: At enrollment, the 89 children exhibited severe immune defects. Antiretroviral therapy raised CD4+ T-lymphocyte counts significantly and decreased viral loads. In contrast, the in vitro immune parameters studied were not improved, except for plasma levels of sTNF-RII which decreased in parallel with the decrease in viral load. In addition, there was a trend towards increased skin test reactivity for the ritonavir-treated children. No differences were seen in the immune parameters whether the patients were treated with mono- or triple therapy. Results obtained after 120 weeks of therapy demonstrated that defective interleukin-12 production was not restored by long-term therapy. CONCLUSIONS: After 6 months of therapy, with the exception of decreased sTNF-RII levels, and a trend towards increased skin test reactivity, restoration of several defective cellular immune responses did not occur despite significantly decreased viral loads and increased CD4+ T-lymphocyte counts.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/immunology , HIV Protease Inhibitors/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adolescent , Apoptosis , CD4 Lymphocyte Count , Child , Child, Preschool , Clinical Trials as Topic , Cytokines/biosynthesis , Cytokines/blood , Drug Therapy, Combination , Humans , Immunity, Cellular , Indinavir/therapeutic use , Infant , Lymphocyte Activation , Ritonavir/therapeutic use , T-Lymphocytes/immunology , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis , Viral Load
12.
Curr Opin Microbiol ; 1(4): 423-9, 1998 Aug.
Article in English | MEDLINE | ID: mdl-10066519

ABSTRACT

The understanding of the factors associated with HIV-1 acquisition and disease progression has been significantly advanced in the past few years. These factors can be broadly defined as intrinsic or acquired and are operative at the levels of disease acquisition and progression or both. Much recent attention has focused on the identification of allelic variants at specific genetic loci that alter either susceptibility to infection or the natural history of disease progression. In addition, a more detailed understanding of the immunologic responses to HIV-1 and factors that perturb these responses has greatly enhanced our understanding of the immunologic control of HIV-1 and the roles of cofactors in HIV-1 acquisition and disease progression.


Subject(s)
Disease Progression , Disease Susceptibility , HIV Infections/etiology , HIV-1/immunology , Cohort Studies , Genetic Variation , HIV Infections/epidemiology , HIV Infections/genetics , HIV Infections/immunology , Humans , Sexually Transmitted Diseases/complications
13.
AIDS ; 11(8): 1013-21, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9223736

ABSTRACT

OBJECTIVE: The present study was designed to determine the effect of immune activation, achieved by influenza vaccination, on plasma HIV RNA levels and immunological parameters including CD4 cell levels, antigen-stimulated T-cell function and apoptotic death of peripheral blood mononuclear cells. DESIGN AND METHODS: Thirty-four HIV-infected individuals and nine uninfected controls were immunized with influenza vaccine and blood was collected at weeks 0, 2, 4 and 16. Plasma was isolated and used for HIV RNA and influenza-specific antibody qualifications. CD4 cell counts, activation and maturation markers of T-lymphocyte subsets were determined by flow cytometry. In vitro T-helper responses, spontaneous- and activation-induced cell death assays were also performed. RESULTS: Influenza-specific humoral and cellular immune responses correlated with CD4 count. Only in patients with CD4 counts > 300 x 10(6)/l there was a modest increase in T-cell responses to influenza virus, which was less than control subjects, observed after vaccination. Immunization had no significant effect on CD4 counts or plasma viral levels in the HIV-positive patients. Baseline apoptosis inversely correlated with CD4 counts and directly correlated with viral load. Activation-induced apoptosis did not change appreciably after vaccination and spontaneous apoptosis increased only in the < 300 CD4 group. CONCLUSION: These results indicate that immune stimulation resulting from influenza vaccination did not significantly change the levels of plasma virus, CD4 cell counts, or activation-induced apoptosis in HIV-infected individuals, although an increase in the T-cell response to influenza and spontaneous apoptosis was observed in the > 300 and < 300 CD4 groups, respectively.


Subject(s)
HIV Infections/immunology , HIV Infections/virology , HIV-1 , Influenza Vaccines/administration & dosage , Antibodies, Viral/immunology , Apoptosis , CD4 Lymphocyte Count , Flow Cytometry , HIV-1/genetics , HIV-1/isolation & purification , Humans , Lymphocyte Activation , RNA, Viral/blood , T-Lymphocytes, Helper-Inducer/cytology , T-Lymphocytes, Helper-Inducer/immunology , Vaccination
14.
Lancet ; 348(9038): 1347-51, 1996 Nov 16.
Article in English | MEDLINE | ID: mdl-8918278

ABSTRACT

BACKGROUND: There is indirect evidence that HIV-1 exposure does not inevitably lead to persistent infection. Heterogeneity in susceptibility to infection could be due to protective immunity. The objective of this study was to find out whether in highly HIV-1-exposed populations some individuals are resistant to infection. METHODS: We did an observational cohort study of incident HIV-1 infection-among 424 initially HIV-1-seronegative prostitutes in Nairobi, Kenya, between 1985 and 1994. 239 women seroconverted to HIV-1 during the study period. Exponential, Weibull, and mixture survival models were used to examine the effect of the duration of follow-up on incidence of HIV-1 infection. The influence of the duration of exposure to HIV-1 through prostitution on seroconversion risk was examined by Cox proportional hazards modelling, with control for other known or suspected risk factors for incident HIV-1 infection. HIV-1 PCR with env, nef, and vif gene primers was done on 43 persistently seronegative prostitutes who remained seronegative after 3 or more years of follow-up. FINDINGS: Modelling of the time to HIV-1 seroconversion showed that the incidence of HIV-1 seroconversion decreased with increasing duration of exposure, which indicates that there is heterogeneity in HIV-1 susceptibility or acquired immunity to HIV-1. Each weighted year of exposure through prostitution resulted in a 1.2-fold reduction in HIV-1 seroconversion risk (hazard ratio 0.83 [95% CI 0.79-0.88], p < 0.0001). Analyses of epidemiological and laboratory data, show that persistent seronegativity is not explained by seronegative HIV-1 infection or by differences in risk factors for HIV-1 infection such as safer sexual behaviours or the incidence of other sexually transmitted infections. INTERPRETATION: We conclude that a small proportion of highly exposed individuals, who may have natural protective immunity to HIV-1, are resistant to HIV-1.


PIP: A cohort study conducted in 1985-94 among 424 prostitutes from Nairobi, Kenya, who were initially human immunodeficiency virus (HIV)-1 seronegative, tended to provide support for the observation that some individuals in highly exposed populations may be resistant to infection. During the 10-year study period, 239 of these women seroconverted. The overall HIV-1 incidence was 42/100 person-years. After the first 2 years of follow up, in which the majority of seroconversions occurred, HIV-1 prevalence reached a plateau and then began a steep decline. To determine whether the risk of HIV-1 infection declined over time as a result of the selection of resistance, incidence rates among women with less than 3 years' versus more than 3 years' duration of prostitution were compared for 1989-93. An increasing protective effect for each seronegative year of exposure was observed. The estimated cumulative protective effect for women practicing prostitution from 1984-93 and remaining seronegative, compared to women who entered prostitution in 1994, was over 100-fold. To rule out the possibility that the decrease in seroconversion with duration of exposure reflected differences in sexual behavior or immunity to sexually transmitted diseases that facilitate HIV transmission, Cox proportional hazards modelling was performed. The weighted duration of prostitution was independently associated with a decreased risk of seroconversion. Each weighted year of exposure resulted in a 1.2-fold decrease in risk. Women who seroconverted were more likely to report 1 or more regular partners and to use condoms with these partners than their counterparts who remained seronegative. Elucidation of the protective mechanisms and the factors mediating the development of immunity against HIV-1 could be important to HIV-1 vaccine research.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , HIV Seronegativity/immunology , HIV-1 , Sex Work , Cohort Studies , Female , HIV Seropositivity/epidemiology , Humans , Immunity, Innate , Incidence , Kenya/epidemiology , Occupational Exposure , Proportional Hazards Models , Prospective Studies , Risk Factors
15.
J Neuropathol Exp Neurol ; 54(3): 320-30, 1995 May.
Article in English | MEDLINE | ID: mdl-7745431

ABSTRACT

Astrocyte cultures from human fetal brain were infected with human immunodeficiency virus (HIV) either as free virus or with a chronically infected lymphoblastoid cell line and monitored for signs of infection. The lymphocytotropic strains HIV3B and HIVSF2(ARV-2) but not the monocytotropic strain HIVAda-M infected the human fetal astrocytes. The infected cells were monitored by immunocytochemistry, detection of p24 antigen in the supernatants and polymerase chain reaction amplification of the proviral DNA. No morphological or cytopathic effects were seen in these cells. Upon co-culture of astrocytes with a lymphoblastoid cell line chronically infected with HIVSF2(ARV-2), the lymphoblastoid cells readily adhered to the astrocytes as determined by a 51Cr adhesion assay and by light and electron microscopy. This cell to cell contact resulted in infection of increased numbers of astrocytes. Similar adhesion of lymphoblasts to microglia was not seen. Thus, astrocytes from human fetal brain can be infected in vitro directly by lymphocytotropic strains of HIV or by adherence to infected lymphoblastoid cells.


Subject(s)
Astrocytes/microbiology , Brain/microbiology , HIV Infections/transmission , HIV-1/physiology , Astrocytes/cytology , Brain/cytology , Cell Adhesion , Cell Communication , Fetus/microbiology , HIV Antigens/analysis , HIV Core Protein p24/analysis , HIV Infections/microbiology , Humans , Lymphocytes/microbiology
16.
J Immunol Methods ; 180(1): 45-51, 1995 Mar 13.
Article in English | MEDLINE | ID: mdl-7897247

ABSTRACT

A rapid and inexpensive method is described where a small amount of serum or plasma was used as the source of DNA for genetic analysis. Using a silica gel matrix DNA was isolated from 50 microliters of archived serum or plasma. The specimens were collected from 13 individuals at two separate time points 3-6 years apart. The polymorphic region of second exon of the MHC class II gene HLA DQA1 was amplified using the polymerase chain reaction (PCR) to sufficient quantities to permit genetic analysis using allele-specific oligonucleotides (ASO). Allelic typing of each specimen was performed and the reproducibility of the method was demonstrated in that in all 13 cases the two independently isolated specimens produced the identical ASO binding patterns. No qualitative difference was noted in the amplified product generated from plasma or serum. This study demonstrates (a) that minute amounts of serum or plasma are able to provide sufficient quantity and quality of DNA to permit genetic analyses (b) and that the source of serum can be archived for many years.


Subject(s)
DNA/blood , Genes, MHC Class II/genetics , HLA-DQ Antigens/genetics , Polymerase Chain Reaction/methods , Alleles , Base Sequence , DNA/isolation & purification , DNA Probes , Female , Genetic Techniques , HLA-DQ alpha-Chains , Humans , Molecular Sequence Data , Oligonucleotide Probes , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...